Intestinal inflammation induces adaptation of P-glycoprotein expression and activity

被引:35
作者
Buyse, M
Radeva, G
Bado, A
Farinotti, R
机构
[1] Fac Pharm Chatenay Malabry, Lab Pharm Clin, UPRES 2706, F-92296 Chatenay Malabry, France
[2] Univ Paris 07, INSERM, U 683, IFR2, F-75018 Paris, France
关键词
Pgp; colitis; DSS; IL10(-/-) mice;
D O I
10.1016/j.bcp.2005.03.025
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent studies suggest that P-glycoprotein (Pgp) encoded by MDR1 gene, may be an important factor in the pathogenesis of inflammatory bowel disease (1BD). In this study, we investigated intestinal Pgp expression and activity: (1) in IL10 deficient (IL10(-/-)) mice which spontaneously develop intestinal inflammation affecting the small and large intestine and (2) in DSS (dextran sodium sulfate)induced rat colitis. In IL10(-/-) enterocolitis mice, rhodamine 123 efflux was reduced by two to three-fold along the small and large intestine. This decrease was associated with a reduction in membrane's Pgp protein levels. A similar three-fold decrease in Pgps activity and expression was observed in the proximal colon in DSS-induced colitis in rats. However, in the non-inflamed ileum in DSS-induced rat colitis, epithelial cell's Pgp activity and protein levels were unexpectedly increased. This effect was specific to local inflammation since LPS induced systemic inflammation did affect neither the intestinal rho 123 efflux transport nor the abundance of the Pgp protein. These data demonstrate for the first time, an impaired function of epithelial Pgp in IL10 deficient enterocolitis mice. They also show an increase in Pgps activity in the non-inflamed ileum in the DSS-induced rat colitis, which may represent an adaptive mechanism to compensate the impaired activity of Pgp in the colon. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1745 / 1754
页数:10
相关论文
共 30 条
  • [1] Proinflammatory role of leptin in experimental colitis in rats -: Benefit of cholecystokinin-B antagonist and β3-agonist
    Barbier, M
    Attoub, S
    Joubert, M
    Bado, A
    Laboisse, C
    Cherbut, C
    Galmiche, JP
    [J]. LIFE SCIENCES, 2001, 69 (05) : 567 - 580
  • [2] Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells
    Belliard, AM
    Tardivel, S
    Farinotti, R
    Lacour, B
    Leroy, C
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (08) : 1103 - 1109
  • [3] Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses
    Berg, DJ
    Davidson, N
    Kuhn, R
    Muller, W
    Menon, S
    Holland, G
    ThompsonSnipes, L
    Leach, MW
    Rennick, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) : 1010 - 1020
  • [4] Bertilsson PM, 2001, J PHARM SCI, V90, P638, DOI 10.1002/1520-6017(200105)90:5<638::AID-JPS1020>3.0.CO
  • [5] 2-L
  • [6] MDR1 Ala893 polymorphism is associated with inflammatory bowel disease
    Brant, SR
    Panhuysen, CIM
    Nicolae, D
    Reddy, DM
    Bonen, DK
    Karaliukas, R
    Zhang, LL
    Swanson, E
    Datta, LW
    Moran, T
    Ravenhill, G
    Duerr, RH
    Achkar, JP
    Karban, AS
    Cho, JH
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (06) : 1282 - 1292
  • [7] Altered development of intestinal intraepithelial lymphocytes in P-glycoprotein-deficient mice
    Eisenbraun, MD
    Mosley, RL
    Teitelbaum, DH
    Miller, RA
    [J]. DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2000, 24 (08) : 783 - 795
  • [8] Eisenbraun MD, 1999, J IMMUNOL, V163, P2621
  • [9] High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
    Farrell, RJ
    Murphy, A
    Long, A
    Donnelly, S
    Cherikuri, A
    O'Toole, D
    Mahmud, N
    Keeling, PWN
    Weir, DG
    Kelleher, D
    [J]. GASTROENTEROLOGY, 2000, 118 (02) : 279 - 288
  • [10] Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro in vivo correlation
    Fricker, G
    Drewe, J
    Huwyler, J
    Gutmann, H
    Beglinger, C
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (07) : 1841 - 1847